Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to crown any winners in the race for the next generation of anti-obesity ...

The pressure on Novo Nordisk redoubled in December 2024. The results of a phase III clinical trial — an advanced stage of research — for its experimental drug CagriSema set off alarm bells: patients ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss treatment. Novo had set a target for patients to lose 25% of their body weight on average over 68 weeks.

Well, it was the age-old bane of pharma firms, namely disappointing late-stage clinical trial results. In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss ...

(Ralf Groene via LinkedIn). Ralf Groene, a key figure in the design of Microsoft’s devices for more than 17 years, has emerged from a short-lived retirement with a new role, as the vice ...

and weaker-than-expected data from Novo's CagriSema. Coming up: We’re awaiting phase 3 data by midyear for Lilly’s leading oral GLP-1 small-molecule therapy, orforglipron, and while we expect ...

At Homecrux, we tried covering every smart home device showcased at the event. Now that the excitement has settled, it’s time to spotlight the standout smart home innovations we saw at CES 2025. From ...

The most prescribed GLP-1 drugs include Ozempic, Wegovy, Mounjaro, CagriSema and Rybelsus. Salty snacks are seeing a slight decline but weren’t on the list of top products experiencing spending ...